Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Norvir

Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 14

Dasatinib, nilotinib, vincristine, Serum concentrations may be increased when co-administered with ritonavir vinblastine resulting in the potential for increased incidence of adverse events.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) vinblastine (HOS-086220) vincristine (HOS-086219) nilotinib (HOS-086218)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 5aa7e9c1a9be2c8668f0fb33afe7a6d1c791ee0bab9de2d3ac4674979a518e31 · Zeichen 18181–18398 im Abschnitt

Wechselwirkungen · Norvir

Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 46

HOS-086422 · Präparat HOS-083284

Dasatinib, nilotinib, vincristine, Serum concentrations may be increased when co-administered with ritonavir resulting in vinblastine the potential for increased incidence of adverse reactions.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) vinblastine (HOS-086220) vincristine (HOS-086219) nilotinib (HOS-086218)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 6b925dd5460d4804efba8b7840c308bf8d008f4af3b7f037d24cd64135bac2b0 · Zeichen 18982–19204 im Abschnitt

Wechselwirkungen · Combivir

Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9

HOS-088522 · Präparat HOS-083663

Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive medicinal products (e.g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole, amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also increase the risk of adverse reactions to zidovudine. If concomitant therapy with Combivir and any of

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flucytosine (HOS-088525) vinblastine (HOS-086220) vincristine (HOS-086219) amphotericin (HOS-088524) pentamidine (HOS-085605) ganciclovir (HOS-085194) doxorubicin (HOS-084538) pyrimethamine (HOS-088523) dapsone (HOS-088141)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 630f15f3aa0679e134693606ce8bb2db3318cda621afe444c3d4ca4706aeffef · Zeichen 11429–11818 im Abschnitt

Wechselwirkungen · Trizivir

TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12

HOS-108573 · Präparat HOS-093047

Concomitant treatment, especially acute therapy, with potentially nephrotoxic or myelosuppressive medicinal products (e.g. systemic pentamidine, dapsone, pyrimethamine, co-trimoxazole, amphotericin, flucytosine, ganciclovir, interferon, vincristine, vinblastine and doxorubicin) may also increase the risk of adverse reactions to zidovudine (see section 4.8). If concomitant therapy with Trizivir and any of these medicinal products is necessary then extra care should be taken in monitoring renal function and haematological parameters and, if required, the dosage of one or more agents should be reduced.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): flucytosine (HOS-088525) vinblastine (HOS-086220) vincristine (HOS-086219) amphotericin (HOS-088524) pentamidine (HOS-085605) ganciclovir (HOS-085194) doxorubicin (HOS-084538) pyrimethamine (HOS-088523) dapsone (HOS-088141)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage fadf52ee0ecc448cf34162a118a4ee0bbbc7fa1f124c0cc7fa32c024f4ee7a11 · Zeichen 16340–16946 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 14

HOS-108873 · Präparat HOS-093083

Due to BCRP (breast cancer resistance protein/ABCG2) and acute P-gp inhibition by lopinavir/ritonavir. Ceritinib Serum concentrations may be Caution should be exercised in increased due to CYP3A and administering ceritinib with P-gp inhibition by Kaletra. Refer to the ceritinib lopinavir/ritonavir. SmPC for dosage adjustment recommendations. Monitor for ADRs related to ceritinib. Most tyrosine kinase Most tyrosine kinase inhibitors Careful monitoring of the tolerance inhibitors such as dasatinib such as dasatinib and nilotinib, of these anticancer agents. and nilotinib, vincristine, also vincristine and vinblastine: vinblastine Risk of increased adverse events due to higher serum concentrations because of CYP3A4 inhibition by lopinavir/ritonavir. Encorafenib Serum concentrations may be Co-administration of encorafenib increased due to CYP3A with Kaletra may increase inhibition by lopinavir/ritonavir. encorafenib exposure which may increase the risk of toxicity, including the risk of serious adverse events such as QT interval prolongation. Co-administration of encorafenib and Kaletra should be avoided. If the benefit is considered to outweigh the risk and Kaletra must be used, patients should be carefully monitored for safety. Fostamatinib Increase in fostamatinib Co-administration of fostamatinib metabolite R406 exposure. with Kaletra may increase fostamatinib metabolite R406 exposure resulting in dose-related adverse events such as hepatotoxicity, neutropenia, hypertension, or diarrhoea. Refer to the fostamatinib SmPC for dose reduction recommendations if such events occur.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ceritinib (HOS-086215) dasatinib (HOS-086217) vinblastine (HOS-086220) vincristine (HOS-086219) encorafenib (HOS-086222) tyrosine (HOS-108875) nilotinib (HOS-086218) fostamatinib (HOS-086224)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f5ee8e193a63fbfc6f13a97d10087b8507fd2ece74570ff6426e080b1664ce91 · Zeichen 15461–19027 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 51

HOS-109008 · Präparat HOS-093083

Due to BCRP (breast cancer resistance protein/ABCG2) and acute P-gp inhibition by lopinavir/ritonavir. Ceritinib Serum concentrations may be Caution should be exercised in increased due to CYP3A and P-gp administering ceritinib with Kaletra. inhibition by lopinavir/ritonavir. Refer to the ceritinib SmPC for dosage adjustment recommendations. Monitor for ADRs related to ceritinib. Most tyrosine kinase Most tyrosine kinase inhibitors Careful monitoring of the tolerance inhibitors such as such as dasatinib and nilotinib, of these anticancer agents. dasatinib and nilotinib, also vincristine and vinblastine: vincristine, vinblastine Risk of increased adverse events due to higher serum concentrations because of CYP3A4 inhibition by lopinavir/ritonavir. Encorafenib Serum concentrations may be Co-administration of encorafenib increased due to CYP3A with Kaletra may increase inhibition by lopinavir/ritonavir. encorafenib exposure which may increase the risk of toxicity, including the risk of serious adverse events such as QT interval prolongation. Co-administration of encorafenib and Kaletra should be avoided. If the benefit is considered to outweigh the risk and Kaletra must be used, patients should be carefully monitored for safety. Fostamatinib Increase in fostamatinib Co-administration of fostamatinib metabolite R406 exposure. with Kaletra may increase fostamatinib metabolite R406 exposure resulting in dose-related adverse events such as hepatotoxicity, neutropenia, hypertension, or diarrhoea. Refer to the fostamatinib SmPC for dose reduction recommendations if such events occur. Ibrutinib Serum concentrations may be Co-administration of ibrutinib and increased due to CYP3A Kaletra may increase ibrutinib inhibition by lopinavir/ritonavir. exposure which may increase the risk of toxicity including risk of tumor lysis syndrome. Co-administration of ibrutinib and Kaletra should be avoided. If the benefit is considered to outweigh the risk and Kaletra must be used, reduce the ibrutinib dose to 140 mg and monitor patient closely for toxicity.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ceritinib (HOS-086215) dasatinib (HOS-086217) vinblastine (HOS-086220) vincristine (HOS-086219) encorafenib (HOS-086222) tyrosine (HOS-108875) nilotinib (HOS-086218) fostamatinib (HOS-086224) ibrutinib (HOS-086226)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage fdf43c7972e8bad9c23624bb28b17126727cc97af42d31ac6b82ada1aa394853 · Zeichen 15203–19620 im Abschnitt

Wechselwirkungen · Kaletra

Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 86

HOS-109082 · Präparat HOS-093083

Due to BCRP (breast cancer resistance protein/ABCG2) and acute P-gp inhibition by lopinavir/ritonavir. Ceritinib Serum concentrations may be Caution should be exercised in increased due to CYP3A and administering ceritinib with Kaletra. P-gp inhibition by Refer to the ceritinib SmPC for lopinavir/ritonavir. dosage adjustment recommendations. Monitor for ADRs related to ceritinib. Most tyrosine kinase Most tyrosine kinase inhibitors Careful monitoring of the tolerance inhibitors such as such as dasatinib and nilotinib, of these anticancer agents. dasatinib and nilotinib, also vincristine and vinblastine: vincristine, vinblastine Risk of increased adverse events due to higher serum concentrations because of CYP3A4 inhibition by lopinavir/ritonavir. Encorafenib Serum concentrations may be Co-administration of encorafenib increased due to CYP3A with Kaletra may increase inhibition by lopinavir/ritonavir. encorafenib exposure which may increase the risk of toxicity, including the risk of serious adverse events such as QT interval prolongation. Co-administration of encorafenib and Kaletra should be avoided. If the benefit is considered to outweigh the risk and Kaletra must be used, patients should be carefully monitored for safety.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ceritinib (HOS-086215) dasatinib (HOS-086217) vinblastine (HOS-086220) vincristine (HOS-086219) encorafenib (HOS-086222) tyrosine (HOS-108875) nilotinib (HOS-086218)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 0214cb99dfae824448a1e6d93d51068bcbe123faea2d2759525b81fd0b437de6 · Zeichen 15510–17920 im Abschnitt

Wechselwirkungen · Vfend

VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12

HOS-109445 · Präparat HOS-093201

Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔ [CYP3A4 inhibitor] The effect of voriconazole on either erythromycin or azithromycin is unknown. Rifabutin Concomitant use of voriconazole [potent CYP450 inducer] and rifabutin should be avoided Voriconazole Cmax  69% unless the benefit outweighs the 300 mg QD Voriconazole AUC  78% risk. The maintenance dose of Compared to voriconazole 200 mg voriconazole may be increased to 300 mg QD (coadministered BID, 5 mg/kg intravenously BID or with voriconazole 350 mg Voriconazole Cmax  4% from 200 mg to 350 mg orally BID)* Voriconazole AUC  32% BID (100 mg to 200 mg orally BID in patients less than 40 kg) (see section 4.2). Careful monitoring of full blood Rifabutin Cmax  195% counts and adverse reactions to 300 mg QD (coadministered Rifabutin AUC  331% rifabutin (e.g., uveitis) is with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is BID)* BID, coadministered with voriconazole. Voriconazole Cmax  104% Voriconazole AUC  87% Rifampicin (600 mg QD) Voriconazole Cmax  93% Contraindicated (see section [potent CYP450 inducer] Voriconazole AUC  96% 4.3) Anti-cancer agents Glasdegib Although not studied, voriconazole If concomitant use cannot be [CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG concentrations of glasdegib and monitoring is recommended (see increase risk of QTc prolongation. section 4.4). Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is [CYP3A4 substrate] may increase tretinoin recommended during treatment concentrations and increase risk of with voriconazole and after its adverse reactions (pseudotumor discontinuation. cerebri, hypercalcaemia). 11 Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be (including but not limited to: may increase plasma avoided, dose reduction of the axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is cobimetinib, dabrafenib, recommended (see section 4.4). dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) [CYP3A4 substrates] Venetoclax Although not studied, voriconazole Concomitant administration of [CYP3A substrate] is likely to significantly increase voriconazole is contraindicated the plasma concentrations of at initiation and during venetoclax. venetoclax dose titration phase (see section 4.3). Dose reduction of venetoclax is required as instructed in venetoclax prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended. Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids not limited to: vincristine and is likely to increase the plasma should be considered. vinblastine) concentrations of vinca alkaloids [CYP3A4 substrates] and lead to neurotoxicity. Anticoagulants Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin coadministered with 300 mg time was approximately 2-fold. time or other suitable BID voriconazole) anticoagulation tests is [CYP2C9 substrate] recommended, and the dose of anticoagulants should be adjusted Other oral coumarins Although not studied, voriconazole accordingly. (including but not limited to: may increase the plasma phenprocoumon, concentrations of coumarins that acenocoumarol) may cause an increase in [CYP2C9 and CYP3A4 prothrombin time. substrates] Anticonvulsants Carbamazepine and Although not studied, Contraindicated (see section long-acting barbiturates carbamazepine and long-acting 4.3) (including but not limited to: barbiturates are likely to phenobarbital, mephobarbital) significantly decrease plasma [potent CYP450 inducers] voriconazole concentrations. Phenytoin Concomitant use of voriconazole [CYP2C9 substrate and potent and phenytoin should be avoided CYP450 inducer] unless the benefit outweighs the risk. Careful monitoring of 300 mg QD Voriconazole Cmax  49% phenytoin plasma levels is Voriconazole AUC  69% recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) azithromycin (HOS-088112) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) erythromycin (HOS-084514) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 92969ff5c9d1e7ffb4a2f7eaf265abd9d2899e7061ac52ea8adefc4d660b4316 · Zeichen 4932–11582 im Abschnitt

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 42–43

HOS-109537 · Präparat HOS-093201

42 Rifabutin Concomitant use of voriconazole [potent CYP450 inducer] and rifabutin should be avoided Voriconazole Cmax  69% unless the benefit outweighs the 300 mg QD Voriconazole AUC  78% risk. The maintenance dose of Compared to voriconazole 200 mg voriconazole may be increased to 300 mg QD (coadministered BID, 5 mg/kg intravenously BID or with voriconazole 350 mg Voriconazole Cmax  4% from 200 mg to 350 mg orally BID)* Voriconazole AUC  32% BID (100 mg to 200 mg orally BID in patients less than 40 kg) (see section 4.2). Careful monitoring of full blood Rifabutin Cmax  195% counts and adverse reactions to 300 mg QD (coadministered Rifabutin AUC  331% rifabutin (e.g., uveitis) is with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is BID)* BID, coadministered with voriconazole. Voriconazole Cmax  104% Voriconazole AUC  87% Rifampicin (600 mg QD) Voriconazole Cmax  93% Contraindicated (see section [potent CYP450 inducer] Voriconazole AUC  96% 4.3) Anti-cancer agents Glasdegib Although not studied, voriconazole If concomitant use cannot be [CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG concentrations of glasdegib and monitoring is recommended (see increase risk of QTc prolongation. section 4.4). Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is [CYP3A4 substrate] may increase tretinoin recommended during treatment concentrations and increase risk of with voriconazole and after its adverse reactions (pseudotumor discontinuation. cerebri, hypercalcaemia). Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be (including but not limited to: may increase plasma avoided, dose reduction of the axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is cobimetinib, dabrafenib, recommended (see section 4.4). dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) [CYP3A4 substrates] Venetoclax Although not studied, voriconazole Concomitant administration of [CYP3A substrate] is likely to significantly increase voriconazole is contraindicated the plasma concentrations of at initiation and during venetoclax. venetoclax dose titration phase (see section 4.3). Dose reduction of venetoclax is required as instructed in venetoclax prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended. Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids not limited to: vincristine and is likely to increase the plasma should be considered. vinblastine) concentrations of vinca alkaloids [CYP3A4 substrates] and lead to neurotoxicity.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) sunitinib (HOS-109453) ribociclib (HOS-109454) tyrosine (HOS-108875) cabozantinib (HOS-109450) bosutinib (HOS-109449) nilotinib (HOS-086218) ibrutinib (HOS-086226)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8012148fb9215ea208ca5169c42c7950e3148c6cc17fe0855dae44a2c3a5b40a · Zeichen 5353–10162 im Abschnitt

Wechselwirkungen · Vfend

VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 75–76

HOS-109603 · Präparat HOS-093201

75 Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be (including but not limited to: may increase plasma avoided, dose reduction of the axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is cobimetinib, dabrafenib, recommended (see section 4.4). dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) [CYP3A4 substrates] Venetoclax Although not studied, voriconazole Concomitant administration of [CYP3A substrate] is likely to significantly increase voriconazole is contraindicated the plasma concentrations of at initiation and during venetoclax. venetoclax dose titration phase (see section 4.3). Dose reduction of venetoclax is required as instructed in venetoclax prescribing information during steady daily dosing; close monitoring for signs of toxicity is recommended. Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids not limited to: vincristine and is likely to increase the plasma should be considered. vinblastine) concentrations of vinca alkaloids [CYP3A4 substrates] and lead to neurotoxicity. Anticoagulants Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin coadministered with 300 mg time was approximately 2-fold. time or other suitable BID voriconazole) anticoagulation tests is [CYP2C9 substrate] recommended, and the dose of anticoagulants should be adjusted Other oral coumarins Although not studied, voriconazole accordingly. (including but not limited to: may increase the plasma phenprocoumon, concentrations of coumarins that acenocoumarol) may cause an increase in [CYP2C9 and CYP3A4 prothrombin time. substrates] Anticonvulsants Carbamazepine and Although not studied, Contraindicated (see section long-acting barbiturates carbamazepine and long-acting 4.3) (including but not limited to: barbiturates are likely to phenobarbital, mephobarbital) significantly decrease plasma [potent CYP450 inducers] voriconazole concentrations. Phenytoin Concomitant use of voriconazole [CYP2C9 substrate and potent and phenytoin should be avoided CYP450 inducer] unless the benefit outweighs the risk. Careful monitoring of 300 mg QD Voriconazole Cmax  49% phenytoin plasma levels is Voriconazole AUC  69% recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) vinblastine (HOS-086220) vincristine (HOS-086219) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f6b81055f3c718e14857cfd38d70a912e61bf8acd5f789552e442ecbfbe65b67 · Zeichen 7792–11614 im Abschnitt

Wechselwirkungen · Noxafil

Noxafil 40 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 8

HOS-114244 · Präparat HOS-094063

Vinca alkaloids Most of the vinca alkaloids (e.g. vincristine and vinblastine) are substrates of CYP3A4. Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4). Posaconazole may increase the plasma concentrations of vinca alkaloids which may lead to neurotoxicity and other serious adverse reactions. Therefore, reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) vincristine (HOS-086219) lead (HOS-085592)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage cbe843f29b5c7b107831c3fb6e847b5786796b654343df4c4a410c21ae1b17e9 · Zeichen 7330–7914 im Abschnitt

Wechselwirkungen · Noxafil

Noxafil 100 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 25

HOS-114294 · Präparat HOS-094063

Vinca alkaloids Most of the vinca alkaloids (e.g. vincristine and vinblastine) are substrates of CYP3A4. Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4). Posaconazole may increase the plasma concentrations of vinca alkaloids which may lead to neurotoxicity and other serious adverse reactions. Therefore,

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) vincristine (HOS-086219) lead (HOS-085592)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage 58a3497e068aaf99989b9c19925322247d385100b19e81df80039021adf974a7 · Zeichen 6750–7165 im Abschnitt

Wechselwirkungen · Noxafil

Noxafil 300 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 48

HOS-114347 · Präparat HOS-094063

Vinca alkaloids Most of the vinca alkaloids (e.g. vincristine and vinblastine) are substrates of CYP3A4. Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4). Posaconazole may increase the plasma concentrations of vinca alkaloids which may lead to neurotoxicity and other serious adverse reactions. Therefore, reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) vincristine (HOS-086219) lead (HOS-085592)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage cbe843f29b5c7b107831c3fb6e847b5786796b654343df4c4a410c21ae1b17e9 · Zeichen 6243–6827 im Abschnitt

Wechselwirkungen · Noxafil

Noxafil 300 mg gastro-resistant powder and solvent for oral suspension · Abschnitt 4.5 · PDF-Seite 72

HOS-114401 · Präparat HOS-094063

Vinca alkaloids Most of the vinca alkaloids (e.g. vincristine and vinblastine) are substrates of CYP3A4. Concomitant administration of azole antifungals, including posaconazole, with vincristine has been associated with serious adverse reactions (see section 4.4). Posaconazole may increase the plasma concentrations of vinca alkaloids which may lead to neurotoxicity and other serious adverse reactions. Therefore, reserve azole antifungals, including posaconazole, for patients receiving a vinca alkaloid, including vincristine, who have no alternative antifungal treatment options.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) vincristine (HOS-086219) lead (HOS-085592)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-24T12:21:00Z · SHA-256 bfc2a27f2fb2c982d1e4beb55db11eb1ad163481d32f08c94b54ec38f96ef5b5 · Passage cbe843f29b5c7b107831c3fb6e847b5786796b654343df4c4a410c21ae1b17e9 · Zeichen 6805–7389 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 18–19

HOS-116385 · Präparat HOS-094447

18 ANTIMYCOBACTERIALS Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and Rifapentine are strong CYP3A inducers and have boosted PREZISTA is not been shown to cause profound decreases recommended. in concentrations of other protease inhibitors, which can result in virological The combination of rifampicin and failure and resistance development boosted PREZISTA is (CYP450 enzyme induction). During contraindicated (see section 4.3). attempts to overcome the decreased exposure by increasing the dose of other protease inhibitors with low dose ritonavir, a high frequency of liver reactions was seen with rifampicin. Rifabutin rifabutin AUC** ↑ 55% A dosage reduction of rifabutin by 150 mg once every other rifabutin Cmin** ↑ ND 75% of the usual dose of day rifabutin Cmax** ↔ 300 mg/day (i.e. rifabutin 150 mg darunavir AUC ↑ 53% once every other day) and darunavir Cmin ↑ 68% increased monitoring for rifabutin related adverse events is warranted darunavir Cmax ↑ 39% ** in patients receiving the sum of active moieties of rifabutin (parent combination with PREZISTA drug + 25-O-desacetyl metabolite) co-administered with ritonavir. In case of safety issues, a further The interaction trial showed a increase of the dosing interval for comparable daily systemic exposure for rifabutin and/or monitoring of rifabutin between treatment at 300 mg rifabutin levels should be once daily alone and 150 mg once every considered. other day in combination with Consideration should be given to PREZISTA/ritonavir (600/100 mg twice official guidance on the daily) with an about 10-fold increase in appropriate treatment of the daily exposure to the active tuberculosis in HIV infected metabolite 25-O-desacetylrifabutin. patients. Furthermore, AUC of the sum of active Based upon the safety profile of moieties of rifabutin (parent drug PREZISTA/ritonavir, the increase + 25-O-desacetyl metabolite) was in darunavir exposure in the increased 1.6-fold, while Cmax remained presence of rifabutin does not comparable. warrant a dose adjustment for Data on comparison with a 150 mg once PREZISTA/ritonavir. daily reference dose is lacking. Based on pharmacokinetic modeling, this dosage reduction of (Rifabutin is an inducer and substrate of 75% is also applicable if patients CYP3A.) An increase of systemic receive rifabutin at doses other exposure to darunavir was observed when than 300 mg/day. PREZISTA co-administered with 100 mg ritonavir was co-administered with Co-administration of PREZISTA rifabutin (150 mg once every other day). co-administered with cobicistat and rifabutin is not recommended. ANTINEOPLASTICS Dasatinib Not studied. Boosted PREZISTA is Concentrations of these medicinal Nilotinib expected to increase these antineoplastic products may be increased when Vinblastine plasma concentrations. co-administered with boosted Vincristine (CYP3A inhibition) PREZISTA resulting in the potential for increased adverse events usually associated with these agents. Caution should be exercised when combining one of these antineoplastic agents with boosted PREZISTA.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) protease (HOS-085623) rifabutin (HOS-086262) vinblastine (HOS-086220) cobicistat (HOS-088111) vincristine (HOS-086219) rifapentine (HOS-116386) ritonavir (HOS-084521) nilotinib (HOS-086218)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 80d9982d7333f238a9b42ff2871813e3ef61b0aafc430c83e6b17352f5e98202 · Zeichen 44997–51632 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 60–61

HOS-116525 · Präparat HOS-094447

60 Rifabutin rifabutin AUC** ↑ 55% A dosage reduction of rifabutin by 150 mg once every other rifabutin Cmin** ↑ ND 75% of the usual dose of day rifabutin Cmax** ↔ 300 mg/day (i.e. rifabutin 150 mg darunavir AUC ↑ 53% once every other day) and darunavir Cmin ↑ 68% increased monitoring for rifabutin related adverse events is warranted darunavir Cmax ↑ 39% ** in patients receiving the sum of active moieties of rifabutin (parent combination with PREZISTA drug + 25-O-desacetyl metabolite) co-administered with ritonavir. In case of safety issues, a further The interaction trial showed a increase of the dosing interval for comparable daily systemic exposure for rifabutin and/or monitoring of rifabutin between treatment at 300 mg rifabutin levels should be once daily alone and 150 mg once every considered. other day in combination with Consideration should be given to PREZISTA/ritonavir (600/100 mg twice official guidance on the daily) with an about 10-fold increase in appropriate treatment of the daily exposure to the active tuberculosis in HIV infected metabolite 25-O-desacetylrifabutin. patients. Furthermore, AUC of the sum of active Based upon the safety profile of moieties of rifabutin (parent drug PREZISTA/ritonavir, the increase + 25-O-desacetyl metabolite) was in darunavir exposure in the increased 1.6-fold, while Cmax remained presence of rifabutin does not comparable. warrant a dose adjustment for Data on comparison with a 150 mg once PREZISTA/ritonavir. daily reference dose is lacking. Based on pharmacokinetic modeling, this dosage reduction of (Rifabutin is an inducer and substrate of 75% is also applicable if patients CYP3A.) An increase of systemic receive rifabutin at doses other exposure to darunavir was observed when than 300 mg/day. PREZISTA co-administered with 100 mg ritonavir was co-administered with rifabutin (150 mg once every other day). ANTINEOPLASTICS Dasatinib Not studied. PREZISTA is expected to Concentrations of these medicinal Nilotinib increase these antineoplastic plasma products may be increased when Vinblastine concentrations. co-administered with PREZISTA Vincristine (CYP3A inhibition) with low dose ritonavir resulting in the potential for increased adverse events usually associated with these agents. Caution should be exercised when combining one of these antineoplastic agents with PREZISTA with low dose ritonavir.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) rifabutin (HOS-086262) vinblastine (HOS-086220) vincristine (HOS-086219) ritonavir (HOS-084521) nilotinib (HOS-086218)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 921968f6843d5fb753e185eb1090f768646fdd146ed0bfdf1dcabbf50411bf6c · Zeichen 36477–41966 im Abschnitt

Wechselwirkungen · Prezista

PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 100–101

HOS-116615 · Präparat HOS-094447

100 ANTIMYCOBACTERIALS Rifampicin Not studied. Rifapentine and rifampicin The combination of rifapentine and Rifapentine are strong CYP3A inducers and have boosted PREZISTA is not been shown to cause profound decreases recommended. in concentrations of other protease inhibitors, which can result in virological The combination of rifampicin and failure and resistance development boosted PREZISTA is (CYP450 enzyme induction). During contraindicated (see section 4.3). attempts to overcome the decreased exposure by increasing the dose of other protease inhibitors with low dose ritonavir, a high frequency of liver reactions was seen with rifampicin. Rifabutin rifabutin AUC** ↑ 55% A dosage reduction of rifabutin by 150 mg once every other rifabutin Cmin** ↑ ND 75% of the usual dose of day rifabutin Cmax** ↔ 300 mg/day (i.e. rifabutin 150 mg darunavir AUC ↑ 53% once every other day) and darunavir Cmin ↑ 68% increased monitoring for rifabutin related adverse events is warranted darunavir Cmax ↑ 39% ** in patients receiving the sum of active moieties of rifabutin (parent combination with PREZISTA drug + 25-O-desacetyl metabolite) co-administered with ritonavir. In case of safety issues, a further The interaction trial showed a increase of the dosing interval for comparable daily systemic exposure for rifabutin and/or monitoring of rifabutin between treatment at 300 mg rifabutin levels should be once daily alone and 150 mg once every considered. other day in combination with Consideration should be given to PREZISTA/ritonavir (600/100 mg twice official guidance on the daily) with an about 10-fold increase in appropriate treatment of the daily exposure to the active tuberculosis in HIV infected metabolite 25-O-desacetylrifabutin. patients. Furthermore, AUC of the sum of active Based upon the safety profile of moieties of rifabutin (parent drug PREZISTA/ritonavir, the increase + 25-O-desacetyl metabolite) was in darunavir exposure in the increased 1.6-fold, while Cmax remained presence of rifabutin does not comparable. warrant a dose adjustment for Data on comparison with a 150 mg once PREZISTA/ritonavir. daily reference dose is lacking. Based on pharmacokinetic modeling, this dosage reduction of (Rifabutin is an inducer and substrate of 75% is also applicable if patients CYP3A.) An increase of systemic receive rifabutin at doses other exposure to darunavir was observed when than 300 mg/day. PREZISTA co-administered with 100 mg ritonavir was co-administered with Co-administration of PREZISTA rifabutin (150 mg once every other day). co-administered with cobicistat and rifabutin is not recommended. ANTINEOPLASTICS Dasatinib Not studied. Boosted PREZISTA is Concentrations of these medicinal Nilotinib expected to increase these antineoplastic products may be increased when Vinblastine plasma concentrations. co-administered with boosted Vincristine (CYP3A inhibition) PREZISTA resulting in the potential for increased adverse events usually associated with these agents. Caution should be exercised when combining one of these antineoplastic agents with boosted PREZISTA.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dasatinib (HOS-086217) protease (HOS-085623) rifabutin (HOS-086262) vinblastine (HOS-086220) cobicistat (HOS-088111) vincristine (HOS-086219) rifapentine (HOS-116386) ritonavir (HOS-084521) nilotinib (HOS-086218)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e88dcbfcf0dab77e559237cbcfe6847cc43133cb297e06b3715555b2ec19c33c · Zeichen 44468–51104 im Abschnitt

Wechselwirkungen · Adcetris

ADCETRIS 50 mg powder for concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 13

HOS-126018 · Präparat HOS-096209

Doxorubicin, vinblastine and dacarbazine (AVD)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) dacarbazine (HOS-089538) doxorubicin (HOS-084538)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2026-03-20T10:51:00Z · SHA-256 a80608da289c54a95c6f3ae56a63c85084ccf90e8e43e395dd22479d252877cb · Passage 2ea4e9254ef41d23121e96ba221d75fbf8c325dd0889eb480bae9ecd6b047d6f · Zeichen 1110–1156 im Abschnitt

Wechselwirkungen · Cresemba

CRESEMBA 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9

HOS-128905 · Präparat HOS-096645

(CYP2B6 induction) Anti-cancer Vinca alkaloids (vincristine, Not studied. No isavuconazole dose vinblastine) Vinca alkaloid concentrations may adjustment necessary. (P-gp substrates) increase. Vinca alkaloids: careful monitoring for any occurrence of (P-gp inhibition) drug toxicity, and dose reduction if required. Cyclophosphamide Not studied. No isavuconazole dose (CYP2B6, CYP3A4 substrate) Active metabolites of adjustment necessary. cyclophosphamide concentrations Cyclophosphamide: careful may increase or decrease. monitoring for any occurrence of lack of efficacy or increased (CYP2B6 induction, CYP3A4 toxicity, and dose adjustment if inhibition) required. Methotrexate Methotrexate: No isavuconazole dose (BCRP, OAT1, OAT3 AUCinf: ↓ 3% adjustment necessary. substrate) Cmax: ↓ 11% Methotrexate: no dose adjustment required. 7-hydroxymetabolite: AUCinf: ↑ 29% Cmax: ↑ 15%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) vincristine (HOS-086219) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage 59c31aafb988b6a4cbbfe1e4ad402b3c90d5d2ef03a62233d8b1bf782f0fbaa2 · Zeichen 10318–11953 im Abschnitt

Wechselwirkungen · Cresemba

CRESEMBA 40 mg hard capsules CRESEMBA 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 31–32

HOS-128987 · Präparat HOS-096645

(CYP2B6 induction) Anti-cancer Vinca alkaloids (vincristine, Not studied. No isavuconazole dose vinblastine) Vinca alkaloid concentrations may adjustment necessary. (P-gp substrates) increase. Vinca alkaloids: careful monitoring for any occurrence of (P-gp inhibition) drug toxicity, and dose reduction if required. Cyclophosphamide Not studied. No isavuconazole dose (CYP2B6, CYP3A4 substrate) Active metabolites of adjustment necessary. cyclophosphamide concentrations Cyclophosphamide: careful may increase or decrease. monitoring for any occurrence of lack of efficacy or increased (CYP2B6 induction, CYP3A4 toxicity, and dose adjustment if inhibition) required. Methotrexate Methotrexate: No isavuconazole dose (BCRP, OAT1, OAT3 AUCinf: ↓ 3% adjustment necessary. substrate) Cmax: ↓ 11% 31 Methotrexate: no dose 7-hydroxymetabolite: adjustment required. AUCinf: ↑ 29% Cmax: ↑ 15%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vinblastine (HOS-086220) vincristine (HOS-086219) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)

Vollständigen Kontext in der EMA-Fachinformation lesen →

Quellennachweis

Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage f297d4e54ac567e12c407f3a10e2d154b27fb2971b0f8c5eb1eafa663ecc87dc · Zeichen 10476–12191 im Abschnitt

Quellenpassagen (26)

Wechselwirkungen · Norvir

Wechselwirkungen · Norvir

Wechselwirkungen · Combivir

Wechselwirkungen · Trizivir

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Kaletra

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Vfend

Wechselwirkungen · Noxafil

Wechselwirkungen · Noxafil

Wechselwirkungen · Noxafil

Wechselwirkungen · Noxafil

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Prezista

Wechselwirkungen · Adcetris

Wechselwirkungen · Cresemba

Wechselwirkungen · Cresemba